Professor Robert J Flanagan

Bob joined ASI in 2018 as Consultant for our Clozapine Therapeutic Drug Monitoring Service. He is an internationally renowned toxicologist with 47 years’ experience in the field, specialising in antipsychotic drugs, notably the use of clozapine.

Bob is a Clinical Scientist with the Department of Precision Medicine, Networked Services at King’s College Hospital NHS Foundation Trust, and Visiting Professor in Psychosis Studies at the Institute of Psychiatry, Psychology and Neuroscience, King’s College London. Among several other appointments, he was formerly Director of the Toxicology Unit, King’s College Hospital NHS Foundation Trust. His particular interests include the treatment of mental illness, especially schizophrenia, and the diagnosis and treatment of substance abuse. Bob regularly advises medical professionals, the police, coroners, and prosecution and defence lawyers on toxicological issues, and has acted as a consultant to the United Nations Office for Drugs and Crime, and the World Health Organization, most recently in Serbia/Kosovo.

Bob pioneered the introduction of clozapine therapeutic drug monitoring (TDM) in the UK in 1993, which has led to a better understanding of the factors affecting clozapine dose requirements in life. He continues to provide advice on all aspects of clozapine TDM to support ASI’s plasma clozapine and norclozapine assay service.

Bob has published over 250 scientific papers – including 36 papers on clozapine – and five books.